$2.58
4.44% today
NYSE, Apr 01, 06:19 pm CET
ISIN
US36870H1032
Symbol
GNLX
Sector
Industry

Genelux Stock price

$2.70
-1.48 35.41% 1M
+0.33 13.92% 6M
+0.34 14.41% YTD
-2.54 48.47% 1Y
-3.30 55.00% 3Y
-3.30 55.00% 5Y
-3.30 55.00% 10Y
NYSE, Closing price Mon, Mar 31 2025
-0.38 12.34%
ISIN
US36870H1032
Symbol
GNLX
Sector
Industry

Key metrics

Market capitalization $101.87m
Enterprise Value $72.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7,284.00
P/S ratio (TTM) P/S ratio 10,187.00
P/B ratio (TTM) P/B ratio 3.57
Revenue growth (TTM) Revenue growth -95.29%
Revenue (TTM) Revenue $10.00k
EBIT (operating result TTM) EBIT $-31.70m
Free Cash Flow (TTM) Free Cash Flow $-21.61m
Cash position $30.90m
EPS (TTM) EPS $-0.96
P/E forward negative
Short interest 8.05%
Show more

Is Genelux a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Genelux Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Genelux forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Genelux forecast:

Buy
100%

Financial data from Genelux

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.01 0.01
94% 94%
100%
- Direct Costs 0.90 0.90
12% 12%
9,000%
-0.90 -0.90
6% 6%
-9,000%
- Selling and Administrative Expenses 11 11
14% 14%
109,000%
- Research and Development Expense 19 19
49% 49%
190,000%
-31 -31
33% 33%
-307,900%
- Depreciation and Amortization 0.90 0.90
12% 12%
9,000%
EBIT (Operating Income) EBIT -32 -32
31% 31%
-316,960%
Net Profit -30 -30
6% 6%
-298,700%

In millions USD.

Don't miss a Thing! We will send you all news about Genelux directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genelux Stock News

Neutral
GlobeNewsWire
4 days ago
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –
Neutral
GlobeNewsWire
7 days ago
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting under...
Neutral
GlobeNewsWire
about 2 months ago
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025.
More Genelux News

Company Profile

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Head office United States
CEO Thomas Zindrick
Employees 24
Founded 2001
Website www.genelux.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today